• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Spotlight on Brescia

2018-12-18News

The EPAD family of trial delivery centres grew to 20 sites in August 2018 with Brescia (Italy) enrolling its first research participant. The team of Dr. Samantha Galluzzi (principal investigator of the EPAD project in Brescia) has currently recruited 15 participants in the EPAD Longitudinal Cohort Study (LCS). We caught up with the Brescia team and asked them a few questions about their best practices and recruitment strategies.

Do you have any top tips to share for running the EPAD LCS efficiently at your site? We think that where possible, having a large group of people working on the LCS is the key! In our site we have four cognitive raters, the principal investigator, a study-dedicated sub-investigator, a research nurse and a neurologist in charge to perform the lumbar puncture. This structure gives us the possibility to schedule, in one day, two screening visits (a lot of our eligible subjects who are willing to participate in the study present as a pair e.g. partners, friends or siblings). When we propose that they undergo their visits together, they are really happy and if one of the two is hesitant about his/her participation, usually thanks to this proposal he/she decides to participate. There’s strength in numbers!
At the moment we are the only Italian site joining the EPAD project and thus we have participants coming from all over Italy. One of the last subjects screened, for example, came from a town which is located about 800 km from our hospital. In this case, we unify as far as possible the procedures foreseen by the protocol and we offer to the participants free accommodation to stay in our city. We find that engaging with our participants greatly helps to promote their participation in the study.

How are you able to find suitable subjects for the cohort? We share the main information about the study with other neurologists and geriatricians who work in our hospital or outside. When they visit a patient accompanied by relatives who are apprehensive about developing the same disease, these practitioners talk about the prevention studies and provide them with our contact details. In the waiting room of the outpatient clinics, people can also find materials about the studies on the prevention of the Alzheimer’s disease and people who are interested in joining can also fill out a form to authorise us to contact them in order to provide detailed information about the LCS. Moreover, word of mouth is an effective way for EPAD! The majority of the subjects we screen suggest to their friends or relatives to join themselves. Our team is also involved in other clinical trials and we speak about the EPAD project with the caregivers of the participants who have been joining in one of them.

Any past or future events/conferences which have been beneficial for recruitment into EPAD? We organise quarterly meetings where our principal investigator speaks about Alzheimer’s disease and what we know about the biomarkers. Usually, during these meetings, we show the animated video illustrating the aim of the EPAD project and we explain in more details the procedures required by the protocol. In this way we want to encourage the audience to ask as many questions as they want and express any concerns they may have in regards to the study (usually related to the lumbar puncture). At the end of the meetings, we collect subscriptions to participate. At the meeting organised on 28 November, 30 of the 50 attendees confirmed their interest to take part in the study! Furthermore, before the screening visit we call each participant in order to check the main inclusion/exclusion criteria and, if all the main criteria are respected, we will proceed to schedule the first visit.

“At the moment there are no other Italian site involved in LCS. We hope that soon there would be other TDC recruiting which might contribute to increase the number of Italian subjects in the cohort”, said Michela Rampini, the EPAD study coordinator in Brescia.

Pictured: From left to right: Mihaela Munteanu (research nurse), Ilaria Passeggia (CDR rater), Valentina Saletti (study coordinator), Anna Mega (recruiter), Dr. Samantha Galluzzi (PI), Dr. Alberto Tagliapietra (sub-I), Michela Rampini (study coordinator), Dr. Davide Vito Moretti (sub-I), back left Nicola Lopizzo and Monica Mazzelli (lab technicians), front left Stefania Provasi (lab technicians) and Sara Gipponi (CDR rater). 

EPAD Update

We currently have 20 sites across Europe enrolling and more than 1,300 research participants screened. We are pleased to announce that 118 new research participants were screened in the EPAD LCS in November. This made November our most successful month to date. A special mention goes to CITA (San Sebastian, Spain) and VUmc (Amsterdam, Netherlands) as these teams screened respectively 23 and 19 new research participants in November. We hope that you will share our positive assessment of the continuing progress of this exciting research collaboration. Stay tuned for more news next year. EPAD thanks you all for the hard work within 2018 and wishes you Merry Christmas and a very happy New Year to all of you and your families!

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Edinburgh Dementia Prevention Summer School 2022
2022-06-30
EPAD at AAIC22!
2022-06-30
ADDI NeuroToolKit Data Hackathon
2022-05-17
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
2022-05-09
First national follow-on study to EPAD LCS launches
2022-04-07
The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
2022-03-10
Latest News
  • Edinburgh Dementia Prevention Summer School 2022
    2022-06-30
  • EPAD at AAIC22!
    2022-06-30
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

The @CenDemPrevent Summer School, a 4-day interactive course on #brainhealth, is designed for clinicians, researchers and students. Space is limited, sign up quickly! 🗓️26-29 September 📍Edinburgh For more info, including programme⤵️ ep-ad.org/edinburgh-deme… pic.twitter.com/FSypbvWK4L

reply retweet favorite
12:38 pm · 2022-06-30
Twitter
EPAD
EPAD
@IMI_EPAD

There’s still time to join the @AlzData #NeuroToolKit #Data Hackathon! Registration closes on 24 June! Participants will work with @IMI_EPAD datasets and utilise the tools on the #ADWorkbench. Interested in participating? ➡️alzheimersdata.org/hackathon twitter.com/IMI_EPAD/statu…

reply retweet favorite
7:21 am · 2022-06-22
Twitter
EPAD
EPAD
@IMI_EPAD

Today, colleagues from @AlzData visited @CenDemPrevent to meet with those involved in various programmes including @IMI_EPAD @AD_PREVENT. Many relevant discussions and great catch-up! #BrainHealth #datasharing #collaboration @craig_ritchie68 @samdansobe @GregorySarah @CindyBirck pic.twitter.com/Mr3trKeuoz

reply retweet favorite
2:43 pm · 2022-06-15
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the new @AlzheimerEurope #DementiaInEurope magazine featuring an article on @IMI_EPAD and its collaboration with @AlzData to make our data findable, accessible and reusable. @craig_ritchie68 ⤵️ alzheimer-europe.org/resource… twitter.com/AlzheimerEurop… pic.twitter.com/vLuW3HMLUh

reply retweet favorite
1:09 pm · 2022-06-14
Twitter
EPAD
EPAD
@IMI_EPAD

Registration will close tomorrow! Register now for the free #Brainhealth2022 conference, taking place next week in Edinburgh ⤵️ brainhealth.scot/brainhealth2… twitter.com/IMI_EPAD/statu…

reply retweet favorite
3:05 pm · 2022-06-09
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT